CRISPR Therapeutics AG (CRSP) EBIAT (2016 - 2025)
Historic EBIAT for CRISPR Therapeutics AG (CRSP) over the last 11 years, with Q3 2025 value amounting to -$106.4 million.
- CRISPR Therapeutics AG's EBIAT fell 2385.21% to -$106.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$488.3 million, marking a year-over-year decrease of 10380.18%. This contributed to the annual value of -$366.3 million for FY2024, which is 13842.98% down from last year.
- As of Q3 2025, CRISPR Therapeutics AG's EBIAT stood at -$106.4 million, which was down 2385.21% from -$208.5 million recorded in Q2 2025.
- In the past 5 years, CRISPR Therapeutics AG's EBIAT registered a high of $759.2 million during Q2 2021, and its lowest value of -$208.5 million during Q2 2025.
- Moreover, its 5-year median value for EBIAT was -$113.2 million (2021), whereas its average is -$65.4 million.
- As far as peak fluctuations go, CRISPR Therapeutics AG's EBIAT skyrocketed by 105312.97% in 2021, and later tumbled by 14175.97% in 2024.
- Quarter analysis of 5 years shows CRISPR Therapeutics AG's EBIAT stood at -$141.2 million in 2021, then grew by 21.72% to -$110.6 million in 2022, then surged by 180.8% to $89.3 million in 2023, then crashed by 141.76% to -$37.3 million in 2024, then plummeted by 185.28% to -$106.4 million in 2025.
- Its EBIAT stands at -$106.4 million for Q3 2025, versus -$208.5 million for Q2 2025 and -$136.0 million for Q1 2025.